Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT01069328. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
Study identification
- NCT ID
- NCT01069328
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Interventions
- Nexavar (Sorafenib, BAY43-9006) Drug
- Bevacizumab Drug
- Paclitaxel Drug
- Carboplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2006
- Primary completion
- Aug 31, 2011
- Completion
- Sep 30, 2011
- Last update posted
- Nov 12, 2013
2006 – 2011
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Lung Cancer trials
Other public records listing Lung Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT06360822: Increasing Equity in Lung Cancer Screening Recruiting
- NCT00001823: Evaluation for NCI Surgery Branch Clinical Research Protocols Recruiting
- NCT07795411: Prospective Multiomic Analysis in Small-Cell Lung Cancer Not yet recruiting
- NCT07792824: Witness Project Lung Not yet recruiting
- NCT06636721: Lung Cancer and Aging: Improving Well-being for Older Adults With Lung Cancer Not yet recruiting
- NCT06577987: Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01069328, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2013 · Synced Sep 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01069328 live on ClinicalTrials.gov.